Oncolytic viruses for cancer immunotherapy

被引：0
作者：
Otto Hemminki
João Manuel dos Santos
Akseli Hemminki
机构：
[1] University Health Network and University of Toronto,Division of Urologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Centre
[2] University of Helsinki,Cancer Gene Therapy Group, Translational Immunology Research Program
[3] Helsinki University Hospital,Department of Urology
[4] TILT Biotherapeutics Ltd,undefined
[5] Helsinki University Hospital Comprehensive Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 13卷
关键词：
Adenovirus; Oncolytic; Tumor; Cancer; Immunotherapy; Review; Immunology; Immune system; Immunosupression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can be used to complement other cancer therapies to gain optimal patient benefits. Historical reports from over a hundred years suggest treatment efficacy and safety with adenovirus and other oncolytic viruses. This is confirmed in more contemporary patient series and multiple clinical trials. Yet, while the first viruses have already been granted approval from several regulatory authorities, room for improvement remains.
引用
收藏
相关论文
共 656 条
[81]  
Schatten WE(2019)Localized treatment with oncolytic adenovirus Delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas Clin Cancer Res 25 6801-1418
[82]  
Smith RR(2017)Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy Cancer Res 77 2052-1947
[83]  
Thomas LB(2018)Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager Cancer Immunol Res 6 605-3043
[84]  
Zielinski T(2010)Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF Mol Ther 18 1874-183
[85]  
Jordan E(2015)Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors Mol Ther 23 321-1223
[86]  
Georgiades J(2019)A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) J Immunother Cancer 7 20-229
[87]  
Zielinski T(2019)The broken cycle: E2F dysfunction in cancer Nat Rev Cancer 19 326-364
[88]  
Cicholska A(2016)Role of telomeres and telomerase in aging and cancer Cancer Discov 6 584-126
[89]  
Jordan E(2010)Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients Cancer Res 70 4297-176
[90]  
Bischoff JR(2007)GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action Cancer Immunol Immunother 56 1653-230
45678910111213